BEAUTYFARM MED(02373) subsidiary intends to acquire Nairier related medical and beauty assets totaling 40 million yuan, adding 19 direct-operated stores.
Beautiful Countryside Healthcare (02373) announced that on November 18, 2025 (after trading hours on the Hong Kong Stock Exchange),...
BEAUTYFARM MED (02373) announced that on November 18, 2025 (after trading hours on the Stock Exchange), the buyer (each a non-wholly owned subsidiary of the company, Neirui'er medical devices and Neirui'er health management) entered into a share transfer agreement with the seller, Guangzhou Beiminseng Enterprise Management Co., Ltd. According to this agreement, the seller intends to sell the target business to the buyer (including 100% equity of medical targets in Dongguan and Zhuhai, and 100% equity of targets in Zhuhai and Dongguan) for a total consideration of 40 million RMB (equivalent to approximately 44 million Hong Kong dollars). After the completion of the acquisition, the company will have a 90% stake in the target company, making it a non-wholly owned subsidiary of the company. This acquisition will lead to the addition of 19 new company-owned stores, including two medical beauty stores and 17 lifestyle beauty stores, further expanding the scale of company-owned stores and deepening the radiation density in the core cities of the Greater Bay Area, simultaneously driving a significant increase in the group's revenue.
It is reported that the medical targets in Dongguan and Zhuhai (Guangzhou Neirui'er Health Medical Investment Co., Ltd.) are mainly engaged in the operation of medical clinics in Dongguan and Zhuhai respectively. The Zhuhai target (Zhuhai Neirui'er Naimi Beauty Technology Co., Ltd.) is mainly engaged in the operation of eight Neirui'er branded beauty and health service stores in Zhuhai. The Dongguan target (Neirui'er Beauty Chain (Dongguan) Co., Ltd.) is mainly engaged in the operation of nine Neirui'er branded beauty and health service stores in Dongguan.
Related Articles

Guotai Haitong: The tipping point for the landing of financial AI applications has arrived, driven by industry and policy.

CONSUN PHARMA (01681) spent 4.4166 million Hong Kong dollars to repurchase 300,000 shares on November 18th.

YONGDA AUTO (03669) spent approximately HK$1.958 million to repurchase 1.2 million shares on November 18th.
Guotai Haitong: The tipping point for the landing of financial AI applications has arrived, driven by industry and policy.

CONSUN PHARMA (01681) spent 4.4166 million Hong Kong dollars to repurchase 300,000 shares on November 18th.

YONGDA AUTO (03669) spent approximately HK$1.958 million to repurchase 1.2 million shares on November 18th.

RECOMMEND

U.S. equities face “key defense lines,” testing bullish conviction; a break would confirm a downtrend into “early next year”
17/11/2025

Year-to-date Hong Kong share buybacks surpass HK$140 billion, with technology and financials leading activity
17/11/2025

Bitcoin’s year-to-date 30% rally “fully erased,” market slips into a bear phase
17/11/2025


